Campbell Noll L, Perkins Anthony J, Bradt Pamela, Perk Sinem, Wielage Ronald C, Boustani Malaz A, Ng Daniel B
Purdue University College of Pharmacy, West Lafayette, Indiana.
Indiana University Center for Aging Research, Regenstrief Institute Inc., Indianapolis, Indiana.
Pharmacotherapy. 2016 Nov;36(11):1123-1131. doi: 10.1002/phar.1843. Epub 2016 Nov 5.
To determine the association between Anticholinergic Cognitive Burden (ACB) score and both cognitive impairment and health care utilization among a diverse ambulatory older adult population.
Retrospective cohort study.
Medication exposure and other clinical data were extracted from the Regenstrief Medical Record System (RMRS), and cognitive diagnosis was derived from a dementia screening and diagnosis study.
A total of 3344 community-dwelling older adults (age 65 yrs and older) who were enrolled in a previously published dementia screening and diagnosis study; of these, 3127 were determined to have no cognitive impairment, and 217 were determined to have cognitive impairment.
The study followed a two-phase screening and comprehensive neuropsychiatric examination to determine a cognitive diagnosis, which defined cognitive impairment as dementia or mild cognitive impairment. The ACB scale was used to identify anticholinergics dispensed in the 12 months prior to screening. A total daily ACB score was calculated by using pharmacy dispensing data from RMRS; each anticholinergic was multiplied by 1, 2, or 3 consistent with anticholinergic burden defined by the ACB scale. The sum of all ACB medications was divided by the number of days with any medication dispensed to achieve the total daily ACB score. Health care utilization included visits to inpatient, outpatient, and the emergency department, and it was determined by using visit data from the RMRS. The overall population had a mean age of 71.5 years, 71% were female, and 58% were African American. Each 1-point increase in mean total daily ACB score was associated with increasing risk of cognitive impairment (odds ratio [OR] 1.13, 95% confidence interval [CI] 1.004-1.27, p=0.043). Each 1-point increase in mean total daily ACB score increased the likelihood of inpatient admission (OR 1.11, 95% CI 1.02-1.29, p=0.014) and number of outpatient visits after adjusting for demographic characteristics, number of chronic conditions, and prior visit history (estimate 0.382, standard error [SE] 0.113; p=0.001). The number of visits to the emergency department was also significantly different after similar adjustments (estimate 0.046, SE 0.023, p=0.043).
Increasing total ACB score was correlated with an increased risk for cognitive impairment and more frequent health care utilization. Future work should study interventions that safely reduce ACB and evaluate the impact on brain health and health care costs.
确定在不同的非卧床老年人群中,抗胆碱能认知负担(ACB)评分与认知障碍及医疗保健利用之间的关联。
回顾性队列研究。
从雷根斯特里夫医疗记录系统(RMRS)中提取药物暴露及其他临床数据,认知诊断源自一项痴呆筛查与诊断研究。
共有3344名社区居住的老年人(年龄65岁及以上)参与了一项先前发表的痴呆筛查与诊断研究;其中,3127人被确定无认知障碍,217人被确定有认知障碍。
该研究采用两阶段筛查和全面的神经精神检查来确定认知诊断,将认知障碍定义为痴呆或轻度认知障碍。ACB量表用于识别筛查前12个月内配发的抗胆碱能药物。通过使用RMRS的药房配药数据计算每日ACB总分;每种抗胆碱能药物根据ACB量表定义的抗胆碱能负担乘以1、2或3。将所有ACB药物的总和除以有任何药物配发的天数,以得出每日ACB总分。医疗保健利用包括住院、门诊和急诊科就诊次数,通过使用RMRS的就诊数据来确定。总体人群的平均年龄为71.5岁,71%为女性,58%为非裔美国人。平均每日ACB总分每增加1分,认知障碍风险增加(比值比[OR]1.13,95%置信区间[CI]1.004 - 1.27,p = 0.043)。在调整人口统计学特征、慢性病数量和既往就诊史后,平均每日ACB总分每增加1分,住院可能性增加(OR 1.11,95% CI 1.02 - 1.29,p = 0.014),门诊就诊次数增加(估计值0.382,标准误[SE]0.113;p = 0.001)。在进行类似调整后,急诊科就诊次数也有显著差异(估计值0.046,SE 0.023,p = 0.043)。
ACB总分增加与认知障碍风险增加及更频繁的医疗保健利用相关。未来的工作应研究安全降低ACB的干预措施,并评估其对脑健康和医疗保健成本的影响。